Comparable stake leader
FMR LLC
SEC ownership of Candel Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001841387.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- CADL on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001841387
- Issuer location
- Needham, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Candel Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
RTW INVESTMENTS, LP
8.8%
Paul B. Manning
7.9%
BlackRock, Inc.
6.6%
ACORN BIOVENTURES, L.P.
5.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
15%
from 13D/G
|
$113,202,510
10,990,535 shares
|
— | 30 Jun 2026 |
| RTW INVESTMENTS, LP |
13F
13D/G
Company
|
8.8%
from 13D/G
|
$66,146,785
6,422,018 shares
|
— | 30 Jun 2026 |
| Paul B. Manning |
3/4/5
13D/G
Director
|
7.9%
from 13D/G
|
$33,268,209
5,750,478 shares
mixed-class rows
|
+$2,999,996 | 30 Jun 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
6.6%
from 13D/G
|
$51,181,112
4,969,040 shares
|
— | 30 Jun 2026 |
| ACORN BIOVENTURES, L.P. |
13D/G
Anders Hove
|
5.2%
|
$14,115,428
2,580,517 shares
|
$0 | 25 Jun 2025 |
| BAKER BROS. ADVISORS LP |
13D/G
|
5%
|
$11,882,723
2,455,108 shares
|
-$2,550,075 | 31 Mar 2025 |
| STATE STREET CORP |
13F
Company
|
4.8%
|
$36,563,177
3,549,823 shares
|
— | 30 Jun 2026 |
| ACORN CAPITAL ADVISORS, LLC |
13F
Company
|
4.8%
|
$36,028,864
3,497,948 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$2,610,076.
Buys
$2,999,996
Insiders: 1
Sells
$389,920
Insiders: 2
Net
+$2,610,076
Shares: +513,011
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 550,458
Shares: 37,447
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 37,447 | $0 | $389,920 | -$389,920 |
| 3-6 | 550,458 | 0 | $2,999,996 | $0 | +$2,999,996 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 24 reporting-owner rows connected to Candel Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
24
Largest Forms 3/4/5 holder
Estuardo Aguilar-Cordova
Net 12M change
+$2,610,076
Latest report
17 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Estuardo Aguilar-Cordova | 10%+ Owner | $52,549,421 | Mixed | 21 Feb 2025 | ||
| Paul B. Manning | Director | $33,268,209 | +$2,999,996 | +9.9% | Mixed | 30 Jun 2026 |
| Christopher Martell | Director | $2,902,260 | Mixed | 23 Jun 2026 | ||
| Laura K. Aguilar | 10%+ Owner | $2,742,246 | Mixed | 06 May 2022 | ||
| Paul Peter Tak | Chief Executive Officer, Director | $1,254,203 | Mixed | 26 Jan 2026 | ||
| Seshu Tyagarajan | Chief Technology Officer | $922,380 | -$154,151 | -14% | Filing P/S | 17 Aug 2026 |
| Francesca Barone | Chief Scientific Officer | $777,905 | -$235,769 | -23% | Filing P/S | 29 Jun 2026 |
| Joseph C. Papa | Director | $508,031 | Mixed | 30 Jun 2026 | ||
| William Garrett Nichols | Chief Medical Officer | $366,401 | Filing P/S | 26 Jan 2026 | ||
| Charles Schoch | Chief Financial Officer | $202,635 | Mixed | 26 Jan 2026 | ||
| Jason Amello | Chief Financial Officer | $181,808 | Mixed | 28 Nov 2023 | ||
| Udi Meirav | Director | $43,940 | Mixed | 26 Jul 2021 | ||
| SMITH ALAN E | Director | $29,293 | Mixed | 26 Jul 2021 | ||
| Gary J. Nabel | Director | $24,998 | Mixed | 23 Jun 2026 | ||
| Nicoletta Loggia | Director | $9,998 | Mixed | 30 Jun 2026 | ||
| Nathan Caffo | Chief Business Officer | $5,400 | Mixed | 29 Jul 2021 | ||
| Edward J. Benz Jr. | Director | Mixed | 23 Jun 2026 | |||
| Susan B. Stewart | Chief Regulatory Officer | Mixed | 11 Apr 2022 | |||
| Mark E. Sims | Chief Commercial Officer | Mixed | 06 Jul 2026 | |||
| Maha Radhakrishnan | Director | Mixed | 23 Jun 2026 |
Recent insider transactions for Candel Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Seshu Tyagarajan | CADL | Common Stock | Sale | -8.35% | $84,000 | $12.00 | -7,000 | 76,865 | 17 Aug 2026 | Direct |
| Mark E. Sims | CADL | Stock Option (Right to Buy) | Award | 285,000 | 285,000 | 06 Jul 2026 | Direct | |||
| Paul B. Manning | CADL | Stock Option (Right to Buy) | Award | 2,199 | 2,199 | 30 Jun 2026 | Direct | |||
| Joseph C. Papa | CADL | Stock Option (Right to Buy) | Award | 1,331 | 1,331 | 30 Jun 2026 | Direct | |||
| Nicoletta Loggia | CADL | Stock Option (Right to Buy) | Award | 381 | 381 | 30 Jun 2026 | Direct | |||
| Francesca Barone | CADL | Common Stock | Sale | -23.3% | $235,769 | $10.06 | -23,447 | 77,362 | 29 Jun 2026 | Direct |
| Seshu Tyagarajan | CADL | Common Stock | Sale | -7.7% | $70,151 | $10.02 | -7,000 | 83,865 | 29 Jun 2026 | Direct |
| Maha Radhakrishnan | CADL | Stock Option (Right to Buy) | Award | 32,000 | 32,000 | 23 Jun 2026 | Direct | |||
| Nicoletta Loggia | CADL | Stock Option (Right to Buy) | Award | 32,000 | 32,000 | 23 Jun 2026 | Direct | |||
| Joseph C. Papa | CADL | Stock Option (Right to Buy) | Award | 32,000 | 32,000 | 23 Jun 2026 | Direct | |||
| Edward J. Benz Jr. | CADL | Stock Option (Right to Buy) | Award | 32,000 | 32,000 | 23 Jun 2026 | Direct | |||
| Christopher Martell | CADL | Stock Option (Right to Buy) | Award | 32,000 | 32,000 | 23 Jun 2026 | Direct | |||
| Renee Gaeta | CADL | Stock Option (Right to Buy) | Award | 32,000 | 32,000 | 23 Jun 2026 | Direct | |||
| Gary J. Nabel | CADL | Stock Option (Right to Buy) | Award | 32,000 | 32,000 | 23 Jun 2026 | Direct | |||
| Diem Nguyen | CADL | Stock Option (Right to Buy) | Award | 32,000 | 32,000 | 23 Jun 2026 | Direct | |||
| Paul B. Manning | CADL | Stock Option (Right to Buy) | Award | 32,000 | 32,000 | 23 Jun 2026 | Direct | |||
| Paul B. Manning | CADL | Stock Option (Right to Buy) | Award | 4,618 | 4,618 | 31 Mar 2026 | Direct | |||
| Joseph C. Papa | CADL | Stock Option (Right to Buy) | Award | 2,795 | 2,795 | 31 Mar 2026 | Direct | |||
| Nicoletta Loggia | CADL | Stock Option (Right to Buy) | Award | 779 | 779 | 31 Mar 2026 | Direct | |||
| Paul B. Manning | CADL | Common Stock | Purchase | 24.9% | $2,999,996 | $5.45 | 550,458 | 2,763,527 | 23 Feb 2026 | By Paul B. Manning Revocable Trust |
| Seshu Tyagarajan | CADL | Stock Option (Right to Buy) | Award | 154,000 | 154,000 | 26 Jan 2026 | Direct | |||
| Charles Schoch | CADL | Stock Option (Right to Buy) | Award | 232,000 | 232,000 | 26 Jan 2026 | Direct | |||
| Paul Peter Tak | CADL | Stock Option (Right to Buy) | Award | 629,000 | 629,000 | 26 Jan 2026 | Direct | |||
| Francesca Barone | CADL | Stock Option (Right to Buy) | Award | 232,000 | 232,000 | 26 Jan 2026 | Direct | |||
| William Garrett Nichols | CADL | Stock Option (Right to Buy) | Award | 136,500 | 136,500 | 26 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.